View More View Less
  • 1 University of Szeged Department of Biotechnology Szeged Hungary
  • | 2 Enviroinvest Corporation Department of Biotechnology Pécs Hungary
  • | 3 University of Pécs Institute of Medical Microbiology and Immunology Pécs Hungary
  • | 4 Hungarian Academy of Sciences Institute of Biophysics, Biological Research Center Szeged Hungary
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $784.00

Cross Mark

The emergence of the multi-drug-resistant Staphylococcus aureus strains has prompted interest in alternatives to conventional drugs. Among the possible options one of the most promising is the therapeutic use of bacteriophages. Over the recent decades, increasing amount of literature has validated the use of bacteriophages for therapy and prophylaxis against drug-resistant staphylococci. This work attempts to review the current knowledge on bacteriophages and their usages for treatment of staphylococcal diseases.

  • Watkins, R.R., David, M.Z., Salata, R.A.: Current concepts on the virulence mechanisms of meticillin-resistant Staphylococcus aureus. J Med Microbiol 61, 1179–1193 (2012).

    Salata R.A. , 'Current concepts on the virulence mechanisms of meticillin-resistant Staphylococcus aureus ' (2012 ) 61 J Med Microbiol : 1179 -1193.

    • Search Google Scholar
  • van Hal, S.J., Jensen, S.O., Vaska, V.L., Espedido, B.A., Paterson, D.L., Gosbell, I.B.: Predictors of mortality in Staphylococcus aureus Bacteremia. ClinMicrobiol Rev 25, 362–386 (2012).

    Gosbell I.B. , 'Predictors of mortality in Staphylococcus aureus Bacteremia ' (2012 ) 25 ClinMicrobiol Rev : 362 -386.

    • Search Google Scholar
  • Rajan, S.: Skin and soft-tissue infections: Classifying and treating a spectrum. Cleve Clin J Med 79, 57–66 (2012).

    Rajan S. , 'Skin and soft-tissue infections: Classifying and treating a spectrum ' (2012 ) 79 Cleve Clin J Med : 57 -66.

    • Search Google Scholar
  • Dryden, M.S.: Complicated skin and soft tissue infection. J Antimicrob Chemother 65, iii35–44 (2010).

    Dryden M.S. , 'Complicated skin and soft tissue infection ' (2010 ) 65 J Antimicrob Chemother : iii35 -44.

    • Search Google Scholar
  • Crum-Cianflone, N.F.: Bacterial, fungal, parasitic, and viral myositis. Clin Microbiol Rev 21, 473–494 (2008).

    Crum-Cianflone N.F. , 'Bacterial, fungal, parasitic, and viral myositis ' (2008 ) 21 Clin Microbiol Rev : 473 -494.

    • Search Google Scholar
  • Uluð, M., Ayaz, C., Celen, M.K.: A case report and literature review: osteomyelitis caused by community-associated methicillin resistant Staphylococcus aureus. J Infect Dev Count 5, 896–900 (2011).

    Celen M.K. , 'A case report and literature review: osteomyelitis caused by community-associated methicillin resistant Staphylococcus aureus ' (2011 ) 5 J Infect Dev Count : 896 -900.

    • Search Google Scholar
  • Boucher, H., Miller, L.G., Razonable, R.R.: Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 51, S183–197 (2010).

    Razonable R.R. , 'Serious infections caused by methicillin-resistant Staphylococcus aureus ' (2010 ) 51 Clin Infect Dis : S183 -197.

    • Search Google Scholar
  • Shirtliff, M.E., Mader, J.T.: Acute septic arthritis. Clin Microbiol Rev 15, 527–544 (2002).

    Mader J.T. , 'Acute septic arthritis ' (2002 ) 15 Clin Microbiol Rev : 527 -544.

  • Pletz, M.W., Burkhardt, O., Welte, T.: Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: Linezolid or vancomycin? — Comparison of pharmacology and clinical efficacy. Eur J Med Res 15, 507–513 (2010).

    Welte T. , 'Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: Linezolid or vancomycin? — Comparison of pharmacology and clinical efficacy ' (2010 ) 15 Eur J Med Res : 507 -513.

    • Search Google Scholar
  • Montanaro, L., Speziale, P., Campoccia, D., Ravaioli, S., Cangini, I., Pietrocola, G., Giannini, S., Arciola, C.R.: Scenery of Staphylococcus implant infections in orthopedics. Future Microbiol. 6, 1329–1349 (2011).

    Arciola C.R. , 'Scenery of Staphylococcus implant infections in orthopedics ' (2011 ) 6 Future Microbiol. : 1329 -1349.

    • Search Google Scholar
  • Chambers, S.T.: Diagnosis and management of staphylococcal infections of pacemakers and cardiac defibrillators. Internal Med J 35, S63–71 (2005).

    Chambers S.T. , 'Diagnosis and management of staphylococcal infections of pacemakers and cardiac defibrillators ' (2005 ) 35 Internal Med J : S63 -71.

    • Search Google Scholar
  • Hadaway, L.: Short peripheral intravenous catheters and infections. J Infus Nursing 35, 230–240 (2012).

    Hadaway L. , 'Short peripheral intravenous catheters and infections ' (2012 ) 35 J Infus Nursing : 230 -240.

    • Search Google Scholar
  • Shah, S.S., Smith, M.J., Zaoutis, T.E.: Device-related infections in children. Pediatr Clin North Am 52, 1189–1208 (2005).

    Zaoutis T.E. , 'Device-related infections in children ' (2005 ) 52 Pediatr Clin North Am : 1189 -1208.

    • Search Google Scholar
  • Ortega, E., Abriouel, H., Lucas, R., Gálvez, A.: Multiple roles of Staphylococcus aureus enterotoxins: Pathogenicity, superantigenic activity, and correlation to antibiotic resistance. Toxins 2, 2117–2131 (2010).

    Gálvez A. , 'Multiple roles of Staphylococcus aureus enterotoxins: Pathogenicity, superantigenic activity, and correlation to antibiotic resistance ' (2010 ) 2 Toxins : 2117 -2131.

    • Search Google Scholar
  • Pinchuk, I.V., Beswick, E.J., Reyes, V.E.: Staphylococcal enterotoxins. Toxins 2, 2177–2197 (2010).

    Reyes V.E. , 'Staphylococcal enterotoxins ' (2010 ) 2 Toxins : 2177 -2197.

  • Dulon, M., Haamann, F., Peters, C., Schablon, A., Nienhaus, A.: MRSAprevalence in Euro-pean healthcare settings: A review. BMC Infect Dis 11, 138 (2011).

    Nienhaus A. , 'MRSAprevalence in Euro-pean healthcare settings: A review ' (2011 ) 11 BMC Infect Dis : 138 -.

    • Search Google Scholar
  • Barber, M.: Methicillin-resistant staphylococci. J Clin Pathol 14, 385–393 (1961).

    Barber M. , 'Methicillin-resistant staphylococci ' (1961 ) 14 J Clin Pathol : 385 -393.

  • Arias, C.A., Murray, B.E.: Antibiotic-resistant bugs in the 21st century — A clinical super-challenge. N Engl J of Med 360, 439–443 (2009).

    Arias C.A. , 'Murray, B.E.: Antibiotic-resistant bugs in the 21st century — A clinical super-challenge ' (2009 ) 360 N Engl J of Med : 439 -443.

    • Search Google Scholar
  • Burkhardt, O., Pletz, M.W., Mertgen, C.-P., Welte, T.: Linezolid — The first oxazolidinone in the treatment of nosocomial MRSA pneumonia. Recent Pat Anti-infect Drug Disc 2, 23–30 (2007).

    Welte T. , 'Linezolid — The first oxazolidinone in the treatment of nosocomial MRSA pneumonia ' (2007 ) 2 Recent Pat Anti-infect Drug Disc : 23 -30.

    • Search Google Scholar
  • Baudoux, P., Lemaire, S., Denis, O., Tulkens, P.M., van Bambeke, F., Glupczynski, Y.: Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureuswith various resistance phenotypes. J Antimicrob Chemother 65, 1228–1236 (2010).

    Glupczynski Y. , 'Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureuswith various resistance phenotypes ' (2010 ) 65 J Antimicrob Chemother : 1228 -1236.

    • Search Google Scholar
  • Bhavnani, S.M., Rubino, C.M., Hammel, J.P., Forrest, A., Dartois, N., Cooper, C.A., Korth-Bradley, J., Ambrose, P.G.: Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother 56, 1065–1072 (2012).

    Ambrose P.G. , 'Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline ' (2012 ) 56 Antimicrob Agents Chemother : 1065 -1072.

    • Search Google Scholar
  • Liu, Y., Cui, J., Wang, R., Wang, X., Drlica, K., Zhao, X.: Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: concurrent bacterial eradication and acquisition of resistance. J Antimicrob Chemother 56, 1172–1175 (2005).

    Zhao X. , 'Selection of rifampicin-resistant Staphylococcus aureus during tuberculosis therapy: concurrent bacterial eradication and acquisition of resistance ' (2005 ) 56 J Antimicrob Chemother : 1172 -1175.

    • Search Google Scholar
  • Howden, B.P., Grayson, M.L.: Dumb and dumber — The potential waste of a useful antistaphylococcal agent: Emerging fusidic acid resistance in Staphylococcus aureus. Clin Infect Dis 42, 394–400 (2006).

    Grayson M.L. , 'Dumb and dumber — The potential waste of a useful antistaphylococcal agent: Emerging fusidic acid resistance in Staphylococcus aureus ' (2006 ) 42 Clin Infect Dis : 394 -400.

    • Search Google Scholar
  • Kurlenda, J., Grinholc, M.: Alternative therapies in Staphylococcus aureus diseases. Acta Biochim Pol 59, 171–184 (2012).

    Grinholc M. , 'Alternative therapies in Staphylococcus aureus diseases ' (2012 ) 59 Acta Biochim Pol : 171 -184.

    • Search Google Scholar
  • Twort, F.W.: An investigation on the nature of ultra-microscopic viruses. Lancet 186, 1241–1243 (1915).

    Twort F.W. , 'An investigation on the nature of ultra-microscopic viruses ' (1915 ) 186 Lancet : 1241 -1243.

    • Search Google Scholar
  • Bruynoghe, R., Maisin, J.: Essais de thérapeutique au moyen du bacteriophage. Comptes Rendus des Séances et Mémoires de la Société de Biologie 85, 1120–1121 (1921).

    Maisin J. , 'Essais de thérapeutique au moyen du bacteriophage ' (1921 ) 85 Comptes Rendus des Séances et Mémoires de la Société de Biologie : 1120 -1121.

    • Search Google Scholar
  • Straub, M.E., Applebaum, M.B.A.: Studies on commercial bacteriophage products. JAMA 100, 110 (1933).

    Applebaum M.B.A. , 'Studies on commercial bacteriophage products ' (1933 ) 100 JAMA : 110 -.

  • Chanishvili, N.: Phage therapy — History from Twort and ďHerelle through Soviet experi-ence to current approaches. Adv Virus Res 83, (2012).

  • Villa, T.G., Veiga-Crespo, P.: Advantages and disadvantages in the use of antibiotics or phages as therapeutic agents. In: Enzybiotics: Antibiotic Enzyme, and Therapeutics. Eds Villa, T.G., Veiga-Crespo, P. JohnWiley & Sons, Inc. ISBN 978-0-470-37655-3, 2010, pp. 27–58.

    Veiga-Crespo P. , '', in Enzybiotics: Antibiotic Enzyme, and Therapeutics , (2010 ) -.

  • Sulakvelidze, A., Kutter, E.: Bacteriophage therapy in humans. In: Bacteriophages: Biology and Applications. Eds Kutter, E., Sulakvelidze, A. Boca Raton, FL: CRC Press, 2005, pp. 377–428.

    Kutter E. , '', in Bacteriophages: Biology and Applications , (2005 ) -.

  • Burman, L.G., Lundblad, G., Cammer, P., Fange, R., Lundborg, M., Soder, P.: Lysozyme — An enzyme of both historical and current interest as a therapeutical agent. Lakartidningen 88, 3665–3668 (1991).

    Soder P. , 'Lysozyme — An enzyme of both historical and current interest as a therapeutical agent ' (1991 ) 88 Lakartidningen : 3665 -3668.

    • Search Google Scholar
  • Shearman, C.A., Jury, K.L., Gasson, M.J.: Controlled expression and structural organization of a Lactococcus lactis bacteriophage lysin encoded by two overlapping genes. Appl and Environ Microbiol 60, 3063–3073 (1994).

    Gasson M.J. , 'Controlled expression and structural organization of a Lactococcus lactis bacteriophage lysin encoded by two overlapping genes ' (1994 ) 60 Appl and Environ Microbiol : 3063 -3073.

    • Search Google Scholar
  • Ibrahim, H.R., Aoki, T., Pellegrini, A.: Strategies for new antimicrobial proteins and peptides: Lysozyme and aprotinin as model molecules. Curr Pharm Des 8, 671–693 (2002).

    Pellegrini A. , 'Strategies for new antimicrobial proteins and peptides: Lysozyme and aprotinin as model molecules ' (2002 ) 8 Curr Pharm Des : 671 -693.

    • Search Google Scholar
  • Touch, V.S., Hayakawa, K., Fukada, Y., Aratani, Sun, Y.: Preparation of antimicrobial reduced lysozyme compatible in food applications. J Agric Food Chem 51, 5154–5161 (2003).

    Aratani S. Y. , 'Preparation of antimicrobial reduced lysozyme compatible in food applications ' (2003 ) 51 J Agric Food Chem : 5154 -5161.

    • Search Google Scholar
  • Delfini, C., Cersosimo, M., Del Prete, V., Strano, M., Gaetano, G., Pagliara, A., Ambrò, S.: Resistance screening essay of wine lactic acid bacteria on lysozyme: Efficacy of lysozyme in unclarified grape musts. J Agric Food Chem 52, 1861–1866 (2004).

    Ambrò S. , 'Resistance screening essay of wine lactic acid bacteria on lysozyme: Efficacy of lysozyme in unclarified grape musts ' (2004 ) 52 J Agric Food Chem : 1861 -1866.

    • Search Google Scholar
  • Hermoso, J.A., Garcia, J.L., Garcia, P.: Taking aimon bacterial pathogens: fromphage therapy to enzybiotics. Curr Opin Microbiol 10, 461–472 (2007).

    Garcia P. , 'Taking aimon bacterial pathogens: fromphage therapy to enzybiotics ' (2007 ) 10 Curr Opin Microbiol : 461 -472.

    • Search Google Scholar
  • Nau, R., Eiffert, H.: Modulation of release of proinflammatory bacterial compounds by antibacterials: Potential impact on course of inflammation and outcome in sepsis and meningitis. Clin Microbiol Rev 15, 95–110 (2002).

    Eiffert H. , 'Modulation of release of proinflammatory bacterial compounds by antibacterials: Potential impact on course of inflammation and outcome in sepsis and meningitis ' (2002 ) 15 Clin Microbiol Rev : 95 -110.

    • Search Google Scholar
  • Wentworth, B.B.: Bacteriophage typing of the Staphylococci. Bacteriol Rev 27, 253–272 (1963).

    Wentworth B.B. , 'Bacteriophage typing of the Staphylococci ' (1963 ) 27 Bacteriol Rev : 253 -272.

    • Search Google Scholar
  • Kwan, T., Liu, J., DuBow, M., Gros, P., Pelletier, J.: The complete genomes and proteomes of 27 Staphylococcus aureus bacteriophages. Proc Natl Acad Sci USA 102, 5174–5179 (2005).

    Pelletier J. , 'The complete genomes and proteomes of 27 Staphylococcus aureus bacteriophages ' (2005 ) 102 Proc Natl Acad Sci USA : 5174 -5179.

    • Search Google Scholar
  • Belcaid, M., Bergeron, A., Poisson, G.: Mosaic graphs and comparative genomics in phage communities. J Comput Biol 17, 1315–1326 (2010) doi: 10.1089/cmb.2010.0108

    Poisson G. , 'Mosaic graphs and comparative genomics in phage communities ' (2010 ) 17 J Comput Biol : 1315 -1326.

    • Search Google Scholar
  • Łobocka, M., Hejnowicz, M.S., Dąbrowski, K., Gozdek, A., Kosakowski, J., Witkowska, M., Ulatowska, M.I., Weber-Dąbrowska, B., Kwiatek, M., Parasion, S., Gawor, J., Kosowska, H., Glowacka, A.: Genomics of staphylococcal Twort-like phages — Potential therapeutics of the post-antibiotic era. Adv Virus Res 83, 143–216 (2012).

    Glowacka A. , 'Genomics of staphylococcal Twort-like phages — Potential therapeutics of the post-antibiotic era ' (2012 ) 83 Adv Virus Res : 143 -216.

    • Search Google Scholar
  • O’Flaherty, S., Ross, R.P., Flynn, J., Meaney, W.J., Fitzgerald, G.F., Coffey, A.: Isolation and characterization of two anti-staphylococcal bacteriophages specific for pathogenic Staphylococcus aureus associated with bovine infections. Lett ApplMicrobiol 41, 482–486 (2005).

    Coffey A. , 'Isolation and characterization of two anti-staphylococcal bacteriophages specific for pathogenic Staphylococcus aureus associated with bovine infections ' (2005 ) 41 Lett ApplMicrobiol : 482 -486.

    • Search Google Scholar
  • Matsuzaki, S., Yasuda, M., Nishikawa, H., Kuroda, M., Ujihara, T., Shuin, T., Shen, Y., Jin, Z., Fujimoto, S., Nasimuzzaman, M.D., Wakiguchi, H., Sugihara, S., Sugiura, T., Koda, S., Muraoka, A., Imai, S.: Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11. J Infect Dis 187, 613–624 (2003).

    Imai S. , 'Experimental protection of mice against lethal Staphylococcus aureus infection by novel bacteriophage phi MR11 ' (2003 ) 187 J Infect Dis : 613 -624.

    • Search Google Scholar
  • Capparelli, R., Parlato, M., Borriello, G., Salvatore, P., Iannelli, D.: Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother 51, 2765–2773 (2007).

    Iannelli D. , 'Experimental phage therapy against Staphylococcus aureus in mice ' (2007 ) 51 Antimicrob Agents Chemother : 2765 -2773.

    • Search Google Scholar
  • “Eliava Institute.” [Online]. Available: http://www.eliava-institute.org/

  • Duckworth, D.H., Gulig, P.A.: Bacteriophages: potential treatment for bacterial infections. BioDrugs 16, 57–62 (2002).

    Gulig P.A. , 'Bacteriophages: potential treatment for bacterial infections ' (2002 ) 16 BioDrugs : 57 -62.

    • Search Google Scholar
  • Brüssow, H.: What is needed for phage therapy to become a reality in Western medicine? Virology 434, 138–142 (2012).

    Brüssow H. , 'What is needed for phage therapy to become a reality in Western medicine ' (2012 ) 434 Virology : 138 -142.

    • Search Google Scholar
  • Merabishvili, M., Pirnay, J.-P., Verbeken, G., Chanishvili, N., Tediashvili, M., Lashkhi, N., Glonti, T., Krylov, V., Mast, J., Van Parys, L., Lavigne, R., Volckaert, G., Mattheus, W., Verween, G., De Corte, P., Rose, T., Jennes, S., Zizi, M., De Vos, D., Vaneechoutte, M.: Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PloS One 4, e4944 (2009).

    Vaneechoutte M. , 'Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials ' (2009 ) 4 PloS One : e4944 -.

    • Search Google Scholar
  • Verbeken, G., Pirnay, J.-P., De Vos, D., Jennes, S., Zizi, M., Lavigne, R., Casteels, M., Huys, I.: Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine. Arch Immunol Ther Exp 60, 161–172 (2012).

    Huys I. , 'Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine ' (2012 ) 60 Arch Immunol Ther Exp : 161 -172.

    • Search Google Scholar
  • Thiel, K.: Old dogma, new tricks — 21st century phage therapy. Nat Biotechnol 22, 31–36 (2004).

    Thiel K. , 'Old dogma, new tricks — 21st century phage therapy ' (2004 ) 22 Nat Biotechnol : 31 -36.

    • Search Google Scholar
All Time Past Year Past 30 Days
Abstract Views 83 83 20
Full Text Views 13 9 1
PDF Downloads 12 10 1